P aeruginosa

August 3, 2017August 3, 2017

Aradigm Asks FDA for New Drug Application for Linhaliq to Treat Bacterial Infection in NCFBE

News

Aradigm is asking the U.S. Food and Drug Administration (FDA) for permission to market its candidate therapy, Linhaliq, to treat non-cystic fibrosis bronchiectasis (NCFBE) with chronic lung infections caused by Pseudomonas aeruginosa. ... Read more

August 6, 2015November 5, 2015

Study Finds That Connectivity of Cystic Fibrosis Centers Increases Risk for Acquisition of Shared P Aeruginosa Strain Infections

Cystic Fibrosis, News

Results from a recent study published in the Lancet Respiratory Medicine show that the connectivity of cystic fibrosis centers, as measured by the movement of patients between them, seems to ... Read more